Merck releases gigantic hunk of expensive pharma data into public domain

7 views
Skip to first unread message

zuzu

unread,
Feb 27, 2009, 3:38:32 PM2/27/09
to diy...@googlegroups.com
http://www.boingboing.net/2009/02/27/merck-releases-gigan.html

Merck releases gigantic hunk of expensive pharma data into public domain
POSTED BY CORY DOCTOROW, FEBRUARY 27, 2009 10:14 AM

John Wilbanks from Science Commons sez, "Merck just pledged a ton of
high-resolution, very expensive data to the public domain, along with
some software and other resources to make it work. It's going into a
new non profit org (disclosure - I am a Board member) called Sage.
This stuff isn't going to be open on day one - it takes a while to
figure out how to give things like this away, and more time to make
them *useful* - but it's on the road."

Sage resulted from the realization that the needs and potentials of
clinical and molecular data to inform drug development are greater
than the resources or capacity of any one company or institute. Sage
is a legacy of successful proof of principle work accomplished at
Rosetta Inpharmatics, a subsidiary of Merck & Co., Inc. in Seattle.
Core human and intellectual property resources from this effort are
seeding Sage’s growth. The primary output from Sage will be an open
access platform available in the public domain. An incubation period
of three to five years is anticipated in which new project data are
generated, critical tools for building and mining disease models are
developed and governing rules for sharing, accessing, and contributing
to the platform are established.

Sage is a distributed research organization with nodes embedded within
core academic partner facilities. Collaborating scientists from both
the nonprofit and commercial sectors will contribute to projects
building and using innovative new databases and tools. More detailed
information will be available soon.


http://sagebase.org/

Vision: Create an open access, integrative bionetwork evolved by
contributor scientists working to eliminate human disease.

Sage is a new, not-for-profit medical research organization
established in 2009 to revolutionize how researchers approach the
complexity of human biological information and the treatment of
disease. Sage’s objectives are:

• to build and support an open access platform and databases for
building innovative new dynamic disease models
• to interconnect scientists as contributors to evolving, integrated
networks of biological data

Background

Sage resulted from the realization that the needs and potentials of
clinical and molecular data to inform drug development are greater
than the resources or capacity of any one company or institute. Sage
is a legacy of successful proof of principle work accomplished at
Rosetta Inpharmatics, a subsidiary of Merck & Co., Inc. in Seattle.
Core human and intellectual property resources from this effort are
seeding Sage’s growth. The primary output from Sage will be an open
access platform available in the public domain. An incubation period
of three to five years is anticipated in which new project data are
generated, critical tools for building and mining disease models are
developed and governing rules for sharing, accessing, and contributing
to the platform are established.

Sage is a distributed research organization with nodes embedded within
core academic partner facilities. Collaborating scientists from both
the nonprofit and commercial sectors will contribute to projects
building and using innovative new databases and tools. More detailed
information will be available soon.

If you would like to receive updates on Sage, please complete our form.

Except where otherwise noted, this work is
licensed under a Creative Commons Attribution 3.0 License.

Dan

unread,
Feb 27, 2009, 5:14:16 PM2/27/09
to DIYbio
I saw some rumblings about this a couple weeks ago - glad to hear
those were true. It's great that this will be available although it
sounds like it'll be a couple years before the entirety of it is
online.
Reply all
Reply to author
Forward
0 new messages